Regeneron Pharmaceuticals (REGN) Profit After Tax (2009 - 2026)

Regeneron Pharmaceuticals' Profit After Tax history runs 18 years deep, the most recent figure standing at $1.3 billion for Q2 2026.

• In Q2 2026, Profit After Tax fell 8.35% year-over-year to $1.3 billion; the TTM figure through Jun 2026 stood at $4.4 billion (down 4.19% YoY), while the FY2025 annual figure was $4.6 billion, up 2.33% from the prior year.
• Profit After Tax for Q2 2026 stood at $1.3 billion, up from $727.2 million in the prior quarter.
• The five-year high for Profit After Tax was $1.5 billion in Q3 2025, with the low at $722.0 million in Q1 2024.
• The 5-year median for Profit After Tax is $1.0 billion (2022), against an average of $1.1 billion.
• The sharpest annual moves came in 2022 and 2024: Profit After Tax sank 72.5% in 2022, then surged 47.9% in 2024.
• Regeneron Pharmaceuticals' Profit After Tax stood at $1.2 billion in 2022, then grew by 4.88% to $1.3 billion in 2023, then sank by 32.33% to $849.6 million in 2024, then gained by 0.41% to $853.1 million in 2025, then surged by 52.02% to $1.3 billion in 2026.
• Business Quant data shows REGN's Profit After Tax at $1.3 billion in Q2 2026, $727.2 million in Q1 2026, and $853.1 million in Q4 2025.